Myeloma Paper of the Day, September 3rd, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Waldenström macroglobulinemia patients have impaired platelet and coagulation function, with plasma displaying slower thrombin generation and platelets contributing less to endogenous thrombin potential.”

Source: Robert Orlowski/X

Waldenström Macroglobulinaemia lymphoma patients have impaired platelet and coagulation function

Authors: Simone A Brysland, Dipti Talaulikar, Sarah M Hicks, James I Hearn, Sidra Asad Ali, Muhammad Gohar Maqbool, Mridula Mokoonlall, Vijay Bhoopalan, Amandeep Kaur, Yee Lin Thong, Robert K Andrews, James C Whisstock, Philip J Crispin Associate Professor, Elizabeth E Gardiner.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.